上海凯赛生物技术股份有限公司 2025年度业绩快报公告

Financial Data Summary - In 2025, the company achieved operating revenue of 3,295.45 million yuan, an increase of 11.41% year-on-year [2] - The total profit reached 631.50 million yuan, up 15.23% year-on-year [2] - The net profit attributable to shareholders was 565.72 million yuan, reflecting a 15.70% increase year-on-year [2] - The net profit after deducting non-recurring gains and losses was 525.92 million yuan, up 13.17% year-on-year [2] - Basic earnings per share were 0.83 yuan, a decrease of 1.19% year-on-year [2] - The weighted average return on net assets was 3.52%, down 0.79 percentage points year-on-year [2] Asset and Equity Growth - As of the end of 2025, total assets amounted to 23,899.70 million yuan, representing a growth of 25.65% from the beginning of the year [2] - The net assets attributable to shareholders increased to 1,770.50 million yuan, a rise of 53.86% from the beginning of the year [2][3] Business Performance Factors - The company's main business continued to expand, driving an increase in sales revenue and gross profit [2] - The net profit was significantly impacted by foreign exchange rates, with a 37.13% year-on-year increase in net profit attributable to shareholders after excluding foreign exchange gains and losses [2]